Market Overview

Thoratec Announces Approval for HeartMate II in Japan

Related THOR
Thoratec Shareholders Approve St. Jude Medical's Acquisition Of Thoratec
Thoratec Announces HeartMate 3 CE Mark Trial Met Primary Endpoint

Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, announced today that the company has received approval from Japan's Ministry of Health, Labour and Welfare to market HeartMate II® ^ as a Bridge-to-Transplantation therapy for patients suffering from advanced heart failure.

Posted-In: News


Related Articles (THOR)

View Comments and Join the Discussion!

Get Benzinga's Newsletters